Metoject® PEN

Metoject PEN


Metoject PEN 50mg/ml is indicated for the treatment of:

• active rheumatoid arthritis in adult patients, polyarthritic forms of severe,

• active juvenile idiopathic arthritis, when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,

• severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, PUVA, and retinoids, and severe psoriatic arthritis in adult patients.

Metoject® Administration Guidelines

Click here for Metoject® administration guidelines

View the SPC...

Download the Metoject PEN SPC. You will need Adobe Reader to view this document.

Get "spc-metoject-pen-01_2017(1).pdf"...


Medicines Information Request

Click here to fill in a medicines information form about this product